Last reviewed · How we verify

Fundação Altino Ventura — Portfolio Competitive Intelligence Brief

Fundação Altino Ventura pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Preservative free artificial tear Preservative free artificial tear marketed Artificial tear / Ocular lubricant Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 1 shared drug class
  2. Andover Research Eye Institute · 1 shared drug class
  3. Aultman Health Foundation · 1 shared drug class
  4. Bausch & Lomb Incorporated · 1 shared drug class
  5. Bp Consulting, Inc · 1 shared drug class
  6. Chong Kun Dang Pharmaceutical · 1 shared drug class
  7. Clinica Oftamologica Zona Sul · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundação Altino Ventura:

Cite this brief

Drug Landscape (2026). Fundação Altino Ventura — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/funda-o-altino-ventura. Accessed 2026-05-18.

Related